Andy Chevigné and his group, RTI-5152-12 is postulated to boost the levels of opioid peptides that bind to classical opioid receptors within the Mind, resulting in heightened painkilling action. The LIH-RTI exploration groups proven a collaboration settlement and submitted a joint patent